Inclusion Criteria:  Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy Histologically or cytologically confirmed endometrioid-type endometrial cancer confined to the uterine corpus No clinical evidence of extra-uterine disease on pre-operative evaluation. Prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy. Age ≥18 years. Life expectancy (estimated survival) of at least 6 months. AST(SGOT)/ALT(SGPT) < 3.0X upper limit of normal Ability to understand and the willingness to sign a written informed consent document.  Exclusion Criteria:  GOG/ECOG Performance Status greater than 2 Non-endometrioid cell type Clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam Previous vaginal, pelvic or abdominal irradiation Chemotherapy, hormone therapy or immunotherapy directed at the present disease Previous pelvic lymphadenectomy or retroperitoneal surgery Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions to compounds of similar chemical or biologic composition Patients with uncontrolled intercurrent illness Patients with psychiatric illness/social situations that would limit compliance with study requirements Pregnant or lactating women